- Carfilzomib, sold
under the
brand name
Kyprolis, is an anti-cancer
medication acting as a
selective proteasome inhibitor. Chemically, it is a tetrapeptide...
-
Kanjinti (trastuzumab-anns) (FDA
approved June 2019)
Krystexxa (pegloticase)
Kyprolis (carfilzomib)
Lumakras (sotorasib)
Mvasi (bevacizumab-awwb)
Neulasta (pegfilgrastim)...
-
representing Darzalex (brand name for daratumumab), and K
representing Kyprolis (brand name for carfilzomib). (Emerging
practice is not to call such drugs...
-
Korsuva Koselugo Kovanaze Krazati Krintafel Krystexxa Kurvelo Kuvan Kuvan Kwell Kybella Kyleena Kymriah Kynamro Kynmobi Kyprolis Kyra
Kytril Kyzatrex...
-
acquired the
rights to
commercialize three Amgen pharmaceuticals, Xgeva,
Kyprolis, and Blincyto, as well as 20
others in development,
investing up to $1...
-
Crews to
develop carfilzomib/
Kyprolis®
through mid-phase 2
clinical trials before being acquired by Onyx in 2009.
Kyprolis® was
approved by the FDA in...
-
comparison to capecitabine).
Carfilzomib (marketed
under the
trade name
Kyprolis) was
approved by the FDA on June 20, 2012, for use in
patients with multiple...
-
boron atom
binds the
catalytic site of the 26S proteasome.
Carfilzomib (
Kyprolis) was
approved by the FDA for
relapsed and
refractory multiple myeloma in...
-
ultimately served as the
parent compound of
multiple myeloma drug
carfilzomib (
Kyprolis).
Based on
successful Phase II
trials of carfilzomib, Onyx Pharmaceuticals...
- $810
million (nominal value). PR-171 is sold by Onyx
Pharmaceuticals as
Kyprolis. Onyx
renamed PR-047 to "ONX 0912" and PR-957 to "ONX 0914". Onyx Pharmaceuticals...
